Cambridge, UK 03 June 2019: Qkine, specialist manufacturer of proteins for stem cell, organoid and regenerative medicine applications has closed a further round of investment. The £550k funding round was led by Cambridge Enterprise and five angel investors – all of whom followed initial seed investments made in April 2018. Joining the original investors [...]
As a structural biologist, one will very quickly realise that protein not only needs to be pure, but it needs to be also homogeneous and the real proof of the protein’s quality is in its specific bioactivity. So,we clearly need different criteria for defining quality and that is what we do at Qkine.
Running for over a decade, the iteams programme partners multi-disciplinary teams of PhD students and postdocs with inventors from the University of Cambridge. As we are a recent spin-out from the academic laboratory of our scientific founder Marko Hyvonen, we have had the pleasure of working with an iteam over the last months. The [...]
We were delighted to be awarded Innovate UK funding to address issues of quality and availability of growth factors for use in organoid technologies. The Qkine R&D team are applying a combination of protein expression, refolding optimisation and structure-guided protein engineering to improve the biological properties and quality of proteins such as R-spondins, TGFβ1, members of the BMP and FGF family proteins.
University of Cambridge spin-out Qkine has closed its seed investment round supported by Cambridge Enterprise, the commercialisation arm of the University, and a team of five angels led by Jim Warwick. The amount is undisclosed. Qkine is a specialist manufacturer of proteins that are used for control of stem cell growth and differentiation. The backing [...]
Cambridge Enterprise and specialist growth factor manufacturer Qkine Ltd sign key licensing deal for Activin A production technology
